Survival with scleroderma—II: A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients

https://doi.org/10.1016/0021-9681(73)90054-4Get rights and content

Abstract

Survival of 358 males first diagnosed scleroderma in a VA hospital was analyzed according to entry characteristics. The overall cumulative survival rate by the life-table method declined to 35 per cent after 7 yr of follow-up. Older patients survived significantly worse than younger (p < 0.001) and this age effect occurred only in the first 2 yr. No racial or geographic differences in survival were found.

All 17 patients with kidneys involved died within 10 months. Men with heart but not kidney involvement had 13 per cent survival after 7 yr and those with lung but neither kidney nor heart had 34 per cent survival. Patients without these circulatory organs involved at entry had the best survival (44 per cent) although far less than expected (91 per cent). In the latter patient group, factors associated with significantly reduced survival were: older age, elevated sedimentation rate, anemia, proteinuria and heavy use of alcohol or cigarettes. None of the common therapies, including corticosteroids influenced survival.

References (18)

  • TA Medsger et al.

    Survival with systemic sclerosis (scleroderma): a life-table analysis of demographic and clinical factors in 309 patients

    Ann Int Med

    (1971)
  • TA Medsger et al.

    The epidemiology of systemic sclerosis (scleroderma)

    Ann Int Med

    (1971)
  • RK Winkelmann

    Classification and pathogenesis of scleroderma

  • TA Medsger et al.

    Factors affecting survivorship in polymyositis: a life-table study of 124 patients

    Arthritis Rheum

    (1971)
  • N Mantel

    Evaluation of survival data and two new rank order statistics arising in its consideration

    Cancer Chemother Rep

    (1966)
  • MH Myers
  • RH Winterbauer

    Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly and subcutaneous calcinosis: syndrome mimicking hereditary hemorrhagic telangiectasia

    Bull Johns Hopkins Hosp

    (1964)
  • MA Sackner
  • DL Tuffanelli et al.

    Systemic scleroderma: clinical study of 727 cases

    Arch Derm (Chicago)

    (1961)
There are more references available in the full text version of this article.

Cited by (119)

  • Systemic Sclerodermas

    2015, Textbook of Pediatric Rheumatology
  • Mortality and survival in systemic sclerosis: Systematic review and meta-analysis

    2014, Seminars in Arthritis and Rheumatism
    Citation Excerpt :

    This last data is obviously a more imprecise data but certainly more real. Several survival and mortality studies from single cohorts [1,3,8–79] and reviews have been published from the last mid-century, reporting data about cumulative survival at different times of follow-up and measured sometimes from the onset of disease and sometimes from the time of diagnosis. This is crucial at the time of meta-analyzing these data and to avoid any bias of selection.

  • Systemic Sclerosis and the Heart

    2014, Rheumatic Disease Clinics of North America
    Citation Excerpt :

    Significant cardiac involvement in SSc portends a poor prognosis. A study by Medsger and Masi10 in 1973 reported that patients with SSc with clinically apparent cardiac disease had an estimated 5-year mortality as high as 70%. Further analyses propose a lower mortality rate.

  • The systemic sclerodermas and related disorders

    2011, Textbook of Pediatric Rheumatology
View all citing articles on Scopus

Assistant Professor of Medicine and Community Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr. Medsger was a Research Associate in the VA Career Development Program and was located at the Memphis VA Hospital during the data collection phase of this study.

Professor of Medicine and Director, Division of Connective Tissue Diseases, University of Tennessee College of Medicine, Memphis, Tennessee.

View full text